Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Presentation Icons
CME
CME
Non-CME
Non-CME
In Person
In Person
On Demand
On Demand
Live Stream
Live Stream
Active Learning
Active Learning
Choose Rheum
Choose Rheum
Emerging Investigator Awardee
Emerging Investigator Awardee

Poster Session

Immunobiology

Poster Session A

Session: (0001–0018) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster I

0001: ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager (TCE) for the Treatment of B Cell-related Autoimmune Diseases

Sunday, October 26, 2025
10:30 AM - 12:30 PM Central Time
Location: Hall F1
Figure 1. ATG-201 showed limited CD3+ T cell binding before CD19-crosslinking. (A) CD19 protein binding KD of ATG-201 detected by SPR. (B) Binding of ATG-201 to Raji, NALM6 and primary B cells. (C) Monovalent binding of ATG-201’s parental anti-CD3 Fab binder to CD3+T cell. (D) Binding of ATG-201 and BMK4 to T cells before CD19 crosslinking. (E) The CD3 binding site is masked by the constant region of the CD19-targeting Fab arm in the absence of CD19 crosslinking by cryo-EM analysis

Figure 2. ATG-201 induced enhanced naïve B cell depletion and reduced cytokine release compared to clinical benchmarks. B cell depletion (A, B) and concentration of the indicated cytokines in the supernatant (C, D) of isolated human PBMC incubated with ATG-201 or Benchmarks for 48 hours.

Figure 3. ATG-201 induces complete B cell depletion in CD34+ hematopoietic stem cells humanized mice with reduced cytokine release. CD34+cell humanized NDG mice were treated with a single dose of 1.5 mg/kg ATG-201 or Bechmark4 (Molar equivalent dose of 1.5 mpk ATG-201). (A) Blood, bone marrow and spleen were collected and analyzed for B cells counts by FACS 3 days (D3), 5 days (D5), 7days (D7), or 14 days (D14) post treatment. (B) Plasma cytokine concentration post treatment.

    Abstract Poster Presenter(s)

  • BH

    Bing Hou, PhD

    Antengene. Corp.
    Shanghai, Shanghai, China

    Disclosure(s): Antengene: Employee (Ongoing), Intellectual Property/Patents (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing)


Background/Purpose: CD19-targeted therapies, such as chimeric antigen receptor (CAR)-T or T-cell engagers (TCE), have been approved for the treatment of B cell malignancies. By depleting autoreactive B cells, CD19-targeted therapies have shown early yet promising efficacy in treating patients with B cell-driven autoimmune diseases. However, the clinical application of TCE continues to be greatly hindered by the unfavorable pharmacokinetics, incomplete B cell depletion and toxicity associated with cytokine release syndrome (CRS). Here we developed a "2+1" CD19 x CD3 TCE, ATG-201, for the treatment of B cell driven autoimmune diseases, which utilizes a steric hindrance-based masking technology and a novel fast-on-fast-off CD3 binder, and effectively depletes B cells with minimal risk of CRS.

Methods: ATG-201 was constructed by introducing a novel fast-on-fast-off, conformational epitope-targeted anti-CD3 single chain fragment variable (scFv) to the hinge region of one of the heavy chains of a CD19 monoclonal antibody. It was evaluated in a series of in vitro and in vivo studies for binding affinity, B cell depletion, cytokine release, anti-disease efficacy and drug developability. The safety and pharmacokinetic (PK) parameters of ATG-201 were evaluated in hCD19/hCD3 knock-in mice, and non-human primates (NHP) using a monkey surrogate TCE antibody.

Results: According to cryo-EM data, the CD3 binding site is masked by the constant region of the CD19-targeting Fab arm in the absence of CD19 cross-linking. ATG-201 showed limited CD3+ T cell binding before CD19-crosslinking (Figure 1). It activated T cells and only in the presence of CD19+ cells. ATG-201 demonstrated stronger B cell depletion activity in PBCMs derived from SLE patient and healthy donors with much lower cytokine release compared to benchmark TCEs in vitro (Figure 2). Single dose of ATG-201 completely and deeply depleted B cells in blood, bone marrow and spleen of CD34+ cells humanized NDG mice (Figure 3). The mouse surrogate CD19xCD3 TCE demonstrated potent efficacy in MOG-EAE model and MRL-lpr mouse SLE model, with deeper B cell depletion observed compared to CD20-targeted TCE. ATG-201 and its monkey surrogate CD19xCD3 TCE exhibited a favorable pharmacokinetic profile in hCD19/hCD3 knock-in mice and NHP respectively. ATG-201 was stable at high concentration (125mg/ml) and under stress conditions. ATG-201 and its monkey surrogate CD19xCD3 TCE were well tolerated in hCD19/hCD3 knock-in mice and NHP.

Conclusion: ATG-201 demonstrates CD19-dependent CD3 binding and activation, inducing effective B cell depletion and anti-disease activity in vitro and in vivo with good PK and safety profile, which warrants further clinical evaluation in the treatment of B cell related autoimmune diseases.